January 09, 2024
Adovate, LLC Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030
ADO-5030 has the potential to transform the treatment of asthma. Charlottesville, VA – January 9, 2024 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing drug candidates targeting the adenosine receptors, today announced its receipt of a